Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.

Published byLeslie Sullivan Modified over 5 years ago

Similar presentations

Presentation on theme: "Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized."— Presentation transcript:

1 Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials  Guillaume Mouillet, Msc, Elisabeth Monnet, MD, Bernard Milleron, MD, Marc Puyraveau, MSc, Elisabeth Quoix, MD, Philippe David, MD, Alain Ducoloné, MD, Olivier Molinier, MD, Gérard Zalcman, MD, PhD, Alain Depierre, MD, Virginie Westeel, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 5, Pages (May 2012) DOI: /JTO.0b013e31824c7d92 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Trial I design. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Trial II design. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Flow chart. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Kaplan–Meier survival plots according to pathologic response: (A) Overall survival (B) Disease-free survival. *Log-rank test. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer  Rodryg Ramlau, MD,

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer  Rodryg Ramlau, MD,
Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Similar presentations

Ads by Google